NewsRx

Search our medical news database

AAT Deficiency

Extensive post-license data reaffirm clinical safety profile of Prolastin

Published in Health and Medicine Week, October 2nd, 2006

The largest safety data set among alpha-1 antitrypsin augmentation (AAT) therapies compiled over the longest period of time reaffirms the clinical safety and tolerability of Prolastin (alpha1-proteinase inhibitor (human)) in treating patients with AAT deficiency.

Presented at the 2006 Annual Congress of the European Respiratory Society, safety data collected since the original approval of Prolastin in 1987 now represent more than 18 years of clinical experience and 40,826 patient-years of exposure. Results demonstrate that Prolastin continues to be well tolerated with respect to drug interactions, overdose, and abuse potential.

Thomas Bernhardt, MD,...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook